Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas
about
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.The development of MDA-7/IL-24 as a cancer therapeuticA serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemoprevention gene therapy approachEnhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand releaseMDA-7/IL-24: multifunctional cancer killing cytokineSuppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic micePhotocytotoxicity of the fluorescent nonsteroidal androgen receptor ligand TDPQ.Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction.Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities.Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition.Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.A combinatory use of adenoviruses expressing melanoma differentiation-associated gene-7 and replication-competent adenoviruses produces synergistic effects on pancreatic carcinoma cells.Synergistic anticancer effects of nanocarrier loaded with berberine and miR-122.
P2860
Q34041932-1049904C-8523-4D7C-A8AE-83AA22D23276Q34163896-F5E10457-EF88-445B-996F-3F325AF2BC5CQ34701049-0C598418-67E9-43BA-82EF-7B1EC5F9F5D2Q34946787-E25E8D32-130E-4147-B47D-DDA8E836614DQ35095082-8F0EC392-4226-484A-B569-D04E3DF0F296Q35189796-8C56A529-6A6D-461F-935F-A1E950E72F94Q35857162-8CBADD77-3BD1-45A1-BD9A-AD301EE779D5Q36248193-AC334565-E066-42ED-9656-062C49F75025Q36545638-EEB8D857-52B4-4DD8-88E8-CDB946919525Q36921374-45038143-4D59-4512-8AC8-5E72C09C4B16Q37561261-F3429F52-F43F-4D67-BECB-49EF9D6A759DQ38174692-3B89F5BC-A8C0-47F0-93DB-B554E17C6E2DQ38799932-BBDB810A-D704-4C37-BA25-1AE13364F776Q38833453-9F2A76FE-660F-4525-B574-C3F3CD2EB124Q40922871-8527E482-FCE2-4B7F-9C87-7EFF967D4073Q55512534-3F087AE4-D936-4A23-8834-18D77C0ECD6B
P2860
Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Strategy for reversing resista ...... tate and pancreatic carcinomas
@ast
Strategy for reversing resista ...... tate and pancreatic carcinomas
@en
type
label
Strategy for reversing resista ...... tate and pancreatic carcinomas
@ast
Strategy for reversing resista ...... tate and pancreatic carcinomas
@en
prefLabel
Strategy for reversing resista ...... tate and pancreatic carcinomas
@ast
Strategy for reversing resista ...... tate and pancreatic carcinomas
@en
P2093
P2860
P356
P1476
Strategy for reversing resista ...... tate and pancreatic carcinomas
@en
P2093
Devanand Sarkar
Ilyas Washington
Irina V Lebedeva
Jennifer A Clark
Nicholas J Turro
Paul B Fisher
Robert L Fine
P2860
P304
P356
10.1073/PNAS.0700042104
P407
P577
2007-02-21T00:00:00Z